Navigation Links
Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting
Date:12/10/2011

on a Special Protocol Assessment (SPA) on the design and planned analysis of the ASPIRE trial.
  • A Phase 3 clinical trial, called the FOCUS trial to support registration in Europe, is evaluating single-agent carfilzomib in patients with relapsed and refractory myeloma who have received three or more prior therapies.
  • An expanded access program is underway in partnership with the Multiple Myeloma Research Foundation for eligible patients in the U.S., with relapsed and refractory multiple myeloma for whom no satisfactory treatment alternatives are available.
  • About Multiple Myeloma
    Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.[ii] Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.[iii]

    About Onyx Pharmaceuticals, Inc.
    Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

    Forward Looking Statements
    This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carf
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons
    2. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
    3. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline
    4. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
    5. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
    6. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
    7. Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting
    8. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
    9. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
    10. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
    11. Radient Pharmaceuticals Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
    (Date:7/30/2014)... 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), ... the cannabis testing and education markets, announced today that ... affairs not previously disclosed or, to its knowledge, any ... action. "We have noticed unusual price and ... trading days," said Steve Barbee , CEO of ...
    (Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
    Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
    ... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... and gastroenterology markets, today announced that it has entered ... a new Phase II development product. The Company has ... Injection and is evaluating the product for the treatment ...
    ... Inc. (NYSE: CRY ), an implantable biological ... that 2011 first quarter financial results will be released ... Company will hold a teleconference call and live webcast ... followed by a question and answer session hosted by ...
    Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
    (Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
    (Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
    (Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
    (Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
    (Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
    Breaking Medicine News(10 mins):Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
    ... , , , BOISE, Idaho, Dec. 28 The research shows, ... bulge becomes a main priority for those setting New Year resolutions ... war; individuals must be prepared to make lifestyle changes starting with ... Light offer two ways to indulge while working off and managing ...
    ... , ... Absolutely Public Relations reviews 2009 key media placement results, plus celebrates client and ... anniversary in business, representing the Colorado Cleantech Industry Association, Bell Aquaculture, Colorado BioScience ... , ...
    ... , WASHINGTON, Dec. 28 CAQH® announced today that ... are the first national health plans to earn certification ... on Operating Rules for Information Exchange® (CORE) Phase II ... in the ongoing development of the CORE rules, which ...
    ... 28, 2009 -- Children regularly exposed to tobacco smoke ... in adulthood. This finding by researchers at Columbia University,s ... may not recover completely from the effects of early-life ... in the December 2009 American Journal of Epidemiology ...
    ... , ASHBURN, Va., Dec. ... data capture and enterprise search solutions , today ... France, has selected the company,s Brainware Distiller(TM) solution to automate ... 150 countries and processes hundreds of thousands of invoices and ...
    ... ... Jack Canfield, Dr. Joe Vitale & Marci Shimoff, Jennifer Nicole Lee is ... and enlightens audiences worldwide with her highly anticipated book "The Mind, Body ... story who has become one of the world,s most accomplished fitness experts. ...
    Cached Medicine News:Health News:Make Your 2010 Resolution and Chill Out with Crystal Light Frozen Treats 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 3Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 4Health News:Aetna and WellPoint Achieve CORE Phase II Certification 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 3Health News:Exposure to tobacco smoke in childhood home associated with early emphysema in adulthood 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 2Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 4
    ... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
    ... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
    ... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
    ... PhotoLightFACIAL facial skin treatment, vascular ... Incorporates a wide range ... multiple hand pieces and large ... the most flexibility. Compact ...
    Medicine Products: